NextCure Inc Share Price Today: Live Updates & Key Insights

NextCure Inc share price today is $9.89, up -0.89%. The stock opened at $10.11 against the previous close of $10.08, with an intraday high of $10.38 and low of $9.6.

NextCure Inc Share Price Chart

NextCure Inc

us-stock
To Invest in {{usstockname}}
us-stock

NextCure Inc Share Price Performance

$9.89 -0.0089(-0.89%) NXTC at 23 Mar 2026 02:33 PM Biotechnology
Lowest Today 9.6
Highest Today 10.38
Today’s Open 10.11
Prev. Close 10.08
52 Week High 15.74
52 Week Low 2.69
Day’s Range: Low 9.6 High 10.38
52-Week Range: Low 2.69 High 15.74
1 day return -
1 Week return -16.04
1 month return -23.51
3 month return -14.52
6 month return +70.51
1 year return +1546.13
3 year return +510.49
5 year return -17.65
10 year return -

NextCure Inc Institutional Holdings

Affinity Asset Advisors, LLC 6.95

Squadron Capital Management LLC 6.66

Sofinnova Ventures 6.25

SILVERARC CAPITAL MANAGEMENT, LLC 4.94

Exome Asset Management LLC 4.63

Pfizer Inc 4.43

Awm Investment Company Inc 3.30

Vanguard Group Inc 2.58

Vanguard Total Stock Mkt Idx Inv 2.04

BOOTHBAY FUND MANAGEMENT, LLC 1.96

Cable Car Capital LLC 1.77

Acadian Asset Management LLC 1.03

Renaissance Technologies Corp 0.94

BlackRock Inc 0.87

Vanguard Institutional Extnd Mkt Idx Tr 0.74

Geode Capital Management, LLC 0.65

CARDIFF PARK ADVISORS, LLC 0.61

Millennium Management LLC 0.37

Fidelity Extended Market Index 0.37

Nomura Healthcare Fund Class I 0.35

Marshall Wace Asset Management Ltd 0.32

Sio Capital Management, LLC 0.31

Barclays PLC 0.16

NT Ext Equity Mkt Idx Fd - L 0.11

Vanguard Instl Ttl Stck Mkt Idx Tr 0.11

Fidelity Total Market Index 0.10

Vanguard Balanced Index Inv 0.10

Fidelity Series Total Market Index 0.08

Spartan Extended Market Index Pool F 0.08

Blackrock Extended Mkt Fund CF 0.07

Northern Trust Extended Eq Market Idx 0.06

Extended Equity Market Fund K 0.06

Spartan Total Market Index Pool G 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

DFA US Core Equity 1 I 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Dimensional US Core Equity 1 ETF 0.02

Fidelity Nasdaq Composite Index 0.02

UBS Group AG 0.02

NextCure Inc Market Status

Strong Buy: 0

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

NextCure Inc Fundamentals

Market Cap 35.57 M

PB Ratio 1.0872

PE Ratio 0.0

Enterprise Value -0.78 M

Total Assets 50.18 M

Volume 23892

NextCure Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:22378000 22.4M, FY19:6347000 6.3M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:22378000 22.4M, FY19:6347000 6.3M

Annual Net worth FY23:-65556000 -65.6M, FY22:-69433000 -69.4M, FY21:-69389000 -69.4M, FY20:-33190000 -33.2M, FY19:-33737000 -33.7M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-633000 -0.6M, Q1/2025:-654000 -0.7M, Q3/2024:null 0.0M, Q2/2024:-701000 -0.7M

Quarterly Net worth Q3/2025:-8624000 -8.6M, Q2/2025:-26808000 -26.8M, Q1/2025:-10976000 -11.0M, Q3/2024:-11540000 -11.5M, Q2/2024:-15404000 -15.4M

About NextCure Inc & investment objective

Company Information NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Organisation Biotechnology

Employees 40

Industry Biotechnology

CEO Mr. Michael S. Richman MSBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

NextCure Inc FAQs

What is the share price of NextCure Inc today?

The current share price of NextCure Inc is $9.89.

Can I buy NextCure Inc shares in India?

Yes, Indian investors can buy NextCure Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy NextCure Inc shares in India?

You can easily invest in NextCure Inc shares from India by:

Can I buy fractional shares of NextCure Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of NextCure Inc?

NextCure Inc has a market cap of $35.57 M.

In which sector does NextCure Inc belong?

NextCure Inc operates in the Biotechnology sector.

What documents are required to invest in NextCure Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of NextCure Inc?

The PE ratio of NextCure Inc is N/A and the PB ratio is 1.09.